WO2020213982A1 - Composition pour la prévention ou le traitement de maladies neurodégénératives utilisant la protéine cd9 et procédé de criblage d'un agent thérapeutique contre les maladies neurodégénératives - Google Patents

Composition pour la prévention ou le traitement de maladies neurodégénératives utilisant la protéine cd9 et procédé de criblage d'un agent thérapeutique contre les maladies neurodégénératives Download PDF

Info

Publication number
WO2020213982A1
WO2020213982A1 PCT/KR2020/005155 KR2020005155W WO2020213982A1 WO 2020213982 A1 WO2020213982 A1 WO 2020213982A1 KR 2020005155 W KR2020005155 W KR 2020005155W WO 2020213982 A1 WO2020213982 A1 WO 2020213982A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
protein
neurodegenerative diseases
inhibitor
activity
Prior art date
Application number
PCT/KR2020/005155
Other languages
English (en)
Korean (ko)
Inventor
황정후
Original Assignee
황정후
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 황정후 filed Critical 황정후
Publication of WO2020213982A1 publication Critical patent/WO2020213982A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention relates to a composition for preventing or treating neurodegenerative diseases using CD9 and a screening method for a therapeutic agent for neurodegenerative diseases, and more particularly, to a prevention or treatment of neurodegenerative diseases comprising an inhibitor of CD9 protein expression or activity as an active ingredient
  • a pharmaceutical composition for use and (a) treating a test substance on cells expressing CD9 protein or mRNA; (b) measuring the expression level of CD9 protein or mRNA in the cells and control cells not treated with the test substance; And (c) selecting a test substance that reduces the expression level of CD9 protein or mRNA compared to the control cells as a candidate substance for treating neurodegenerative diseases.
  • Neurodegenerative diseases are associated with symptoms when nerve cells degenerate, lose function, and often die. Patients with neurodegenerative diseases may experience extreme degeneration in cognitive or motor abilities, and because these diseases are primarily progressive, their quality of life and expectations for life may be significantly reduced as a result. .
  • Parkinson's Disease PD
  • AD Alzheimer's disease
  • ALS amyotrophic lateral sclerosis
  • HD Huntington's disease
  • Frontotemporal Dementia cortical-basal ganglia.
  • Degeneration Cortico Basal Degeneration
  • PSP progressive supranuclear palsy
  • dementia is a disease that causes the most extensive cell damage and accompanies degenerative mental disorders.
  • major symptoms such as memory impairment and loss of judgment are well known.
  • Dementia can be broadly divided into vascular dementia caused by stenosis or blockage of cerebrovascular blood vessels, Alzheimer's dementia, which is known to be caused by accumulation of beta-amyloid protein in the brain, and mixed dementia caused by a combination of these two causes.
  • Alzheimer's dementia accounts for the largest proportion of dementia patients, and a recent study reports that 1 in 85 people will have the disease by 2050, of which 43% need special care. (Prabhulkar S, Piatyszek R, et al. J Neurochem., 2012, 122, 374-381).
  • Among neurodegenerative diseases, Alzheimer's disease is largely classified into hereditary Alzheimer's disease and sporadic Alzheimer's disease (SAD).
  • SAD sporadic Alzheimer's disease
  • Hereditary Alzheimer's disease accounts for 5-10% of all Alzheimer's patients.
  • the hyperphosphorylated, aggregated tau is a central neuropathological feature of Alzheimer's disease and many human neurodegenerative diseases.
  • significant reports have been published on the role of tau in recent years.
  • the development of various tau transgenic animal models has made significant progress in tau dependent pathology, including the propagation of tau pathology from neurons to other cells and interactions between A ⁇ and tau. According to this pathology and tau-related biomarkers, new treatments have been obtained. Nevertheless, the etiological factors leading to neurodegeneration and the exact mechanism of tau-mediated neurotoxicity still need to be elucidated, and the exact cause of the onset is not known to date (Ann Transl Med. 2018 May; 6(10). ): 175.)
  • Alzheimer's disease pathological features include senile plaques that accumulate outside of nerve cells, neurofibrilary tangles that look like tangled bundles of threads in the cell body of nerve cells, and neuroal loss. And the like. These pathological features appear in both hereditary Alzheimer's disease and sporadic Alzheimer's disease. Among them, a toxic protein called amyloid ⁇ peptide (A ⁇ ) has been revealed as a major constituent of senile spots. Amyloid beta peptides are insoluble peptides consisting of 40 to 42 amino acids resulting from abnormal cleavage of amyloid proproteins.
  • amyloid beta peptide is regarded as a major pathogenic material for Alzheimer's disease.
  • the overall pathogenesis of Alzheimer's disease is that when mutations in the presenilin 1 and 2 genes (PS 1 and 2) occur, the amyloid proprotein is abnormally cleaved by ⁇ -secretase and amyloid beta peptide is produced. do. It is known that necrosis of cranial nerve cells occurs due to the produced amyloid beta peptide, which causes Alzheimer's disease.
  • CD9 is a tetraspanin-based cell membrane glycoprotein having a molecular weight of 24 to 27 kDa, and there are 34 tetraspanins in mammals, and 33 of them have been identified in humans.
  • Each tetraspanin contains cell adhesion and migration, platelet activity and aggregation, fusion of egg and sperm during fertilization in mammals, development and metastasis of cancer, humoral immune response and allergic response, human immunodeficiency virus-1 (HIV It is known as an antigen that plays an important role in -1) and influenza virus replication.
  • the present inventors have repeatedly conducted extensive research to develop a new treatment for neurodegenerative diseases, and found that inhibition of the expression or activity of the CD9 protein can improve symptoms such as memory loss caused by degenerative brain lesions.
  • the invention was completed.
  • compositions for the prevention or treatment of neurodegenerative diseases consisting of an inhibitor of the expression or activity of the CD9 protein as an active ingredient.
  • compositions for the prevention or treatment of neurodegenerative diseases consisting essentially of an inhibitor of expression or activity of a CD9 protein as an active ingredient.
  • Another object of the present invention is the steps of (a) treating a test substance on cells expressing CD9 protein or mRNA; (b) measuring the expression level of CD9 protein or mRNA in the cells and control cells not treated with the test substance; And (c) selecting a test substance that reduces the expression level of CD9 protein or mRNA compared to the control cells as a candidate substance for treating a neurodegenerative disease.
  • Another object of the present invention is to provide a use of an inhibitor of expression or activity of a CD9 protein for preparing a preparation for preventing or treating neurodegenerative diseases.
  • Another object of the present invention is to provide a method for treating neurodegenerative diseases comprising administering to an individual in need thereof an effective amount of a composition comprising an inhibitor of CD9 protein expression or activity as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising an inhibitor of expression or activity of CD9 protein as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising an inhibitor of CD9 protein expression or activity as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating neurodegenerative diseases essentially consisting of an inhibitor of CD9 protein expression or activity as an active ingredient.
  • the present invention comprises the steps of: (a) treating cells expressing CD9 protein or mRNA with a test substance; (b) measuring the expression level of CD9 protein or mRNA in the cells and control cells not treated with the test substance; And (c) selecting a test substance that reduces the expression level of CD9 protein or mRNA compared to the control cells as a candidate substance for treating a neurodegenerative disease.
  • the present invention provides a use of an inhibitor of expression or activity of a CD9 protein to prepare a preparation for preventing or treating neurodegenerative diseases.
  • the present invention provides a method for treating neurodegenerative diseases comprising administering to an individual in need thereof an effective amount of a composition comprising an inhibitor of CD9 protein expression or activity as an active ingredient. to provide.
  • the present invention provides a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising an inhibitor of expression or activity of CD9 protein as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising an inhibitor of CD9 protein expression or activity as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating neurodegenerative diseases essentially consisting of an inhibitor of CD9 protein expression or activity as an active ingredient.
  • treatment refers to suppression of occurrence or recurrence of a disease, alleviation of symptoms, reduction of direct or indirect pathological consequences of a disease, reduction of disease progression rate, improvement of disease state, improvement, alleviation or improved prognosis. do.
  • prevention' as used in the present invention means any action that suppresses the onset or delays the progression of a disease.
  • 'Protein' is used interchangeably with'polypeptide' or'peptide', for example, refers to a polymer of amino acid residues as commonly found in proteins in nature.
  • a'fragment' of the CD9 protein refers to a peptide of a portion of the CD9 protein.
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • DNA is composed of four bases: adenine (A), guanine (G), cytosine (C), and thymine (T), and RNA is composed of uracil (U) instead of thymine.
  • A forms a hydrogen bond with T or U
  • C forms a hydrogen bond with the G base, and the relationship between these bases is called'complementary'.
  • mRNA messenger RNA or messenger RNA
  • RNA messenger RNA or messenger RNA
  • the neurodegenerative disease refers to a disease related to symptoms that appear when nerve cells degenerate, lose function, and die, and Alzheimer's disease, dementia, mild cognitive impairment, Parkinson's disease, progressive nuclear paralysis, multi-system Atrophy, Olive Nucleus-Peripheral-Cerebral Atrophy (OPCA), Shy-Drager Syndrome, Stroke-Black Matter Degeneration, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS), Essential Tremors, Cortical-basal Nucleus Degeneration, Diffuse Lewy Body Disease , Parkin's-ALS-dementia complex, Niemann-Pick disease, Pick's disease, cerebral ischemia, and may be selected from the group consisting of cerebral infarction, but is not limited thereto, and most preferably Alzheimer's disease or dementia. have.
  • OPCA Olive Nucleus-Peripheral-Cerebral Atrophy
  • ALS Amyotrophic Lateral Sclerosis
  • Essential Tremors Cortical-basal Nucle
  • CD9 is a tetraspanin-based cell membrane glycoprotein having a molecular weight of 24 to 27 kDa, and there are 34 tetraspanins in mammals, and 33 of them have been identified in humans.
  • Each tetraspanin contains cell adhesion and migration, platelet activity and aggregation, fusion of egg and sperm during fertilization in mammals, development and metastasis of cancer, humoral immune response and allergic response, human immunodeficiency virus-1 (HIV It is known as an antigen that plays an important role in -1) and influenza virus replication.
  • the term'CD9' as used herein is a cell surface glycoprotein receptor of about 24 to 27 kDa belonging to a member of the tetraspanin family, and a signal that plays an important role in regulating cell development, activity, growth and motility. It is known to regulate signal transduction events. In addition, it can regulate cell adhesion and cell migration, and induce platelet activation and aggregation, which are involved in platelet-induced endothelial cell proliferation. In addition, it is involved in various phenomena within cells, such as promoting muscle cell fusion and contributing to myotube maintenance.
  • the CD9 protein in the present invention may be derived from mammals, preferably derived from humans. Most preferably, the CD9 protein in the present invention comprises the amino acid sequence of human CD9 isoform 1 (NP_001760.1) represented by SEQ ID NO: 1 or human CD9 isoform 2 (NP_001317241.1) represented by SEQ ID NO: 2 Characterized in that (NCBI Genbank accession number in parentheses).
  • the CD9 protein expression inhibitor is any one selected from the group consisting of an antisense oligonucleotide complementary to CD9 mRNA, siRNA, shRNA, miRNA, ribozyme, crispr-cas9, DNAzyme, and protein nucleic acid (PNA). It can be.
  • the CD9 mRNA most preferably comprises a nucleotide sequence of human CD9 mRNA transcript variant 1 (NM_001769.3) represented by SEQ ID NO: 3 or human CD9 mRNA transcript variant 2 (NM_001330312.1) represented by SEQ ID NO: 4 (NCBI Genbank accession number in parentheses).
  • SEQ ID NO: 4 NCBI Genbank accession number in parentheses.
  • the CD9 protein expression inhibitor according to the present invention may preferably be a shRNA that binds complementarily to CD9 mRNA and causes degradation of the mRNA.
  • the'siRNA small interfering RNA or short interfering RNA or silencing RNA
  • the'siRNA is artificially introduced into the cell to induce degradation of the mRNA of a specific gene, thereby preventing protein translation, thereby inhibiting gene expression.
  • It is a short double-stranded RNA that causes RNA interference, and is composed of 20 to 25 nucleotides complementary to a specific site of the target mRNA.
  • an antisense strand complementary to the target mRNA binds to the RNA-induced silencing complex (RISC) protein complex and binds to the target mRNA, and the argonaute protein in the RISC complex cleaves and degrades the target mRNA. It suppresses the expression of specific genes through mechanisms such as suppressing the binding of proteins and ribosomes important for protein translation with mRNA.
  • RISC RNA-induced silencing complex
  • the shRNA is a substance that induces RNA interference, and is a molecule having a double-stranded structure in the molecule and a hairpin-like structure by partially containing a palindromic nucleotide sequence in a single-stranded RNA.
  • a shRNA expression plasmid is introduced into a cell and expressed, a 21-23 base pair siRNA is generated by RNase III (ribonuclease III) enzyme called dicer in the cell to induce RNAi.
  • the siRNA or shRNA may be obtained by applying various modifications to improve the stability of the oligonucleotide in vivo, impart resistance to nuclease enzymes, and reduce non-specific immune responses.
  • the modification of the oligonucleotide is the OH group at the 2′ carbon position of the sugar structure in one or more nucleotides -CH 3 (methyl), -OCH 3 (methoxy), -NH 2 , -F, -O-2-methoxyethyl, -O-propyl, -O-2-methylthioethyl, -O-3-aminopropyl, -O-3-dimethylaminopropyl, -ON-methylacetamido or -O-dimethylami Modification by substitution with dooxyethyl; Modification in which oxygen in the sugar structure in the nucleotide is substituted with sulfur; Alternatively, one or more modifications selected from modifications of nucleotide bonds to phosphoroth
  • the CD9 protein activity inhibitor may be any one selected from the group consisting of compounds, peptides, peptide mimetics, aptamers, antibodies, natural extracts, and synthetic compounds that specifically bind to CD9 protein.
  • the pharmaceutical composition according to the present invention can be variously formulated according to the route of administration by a method known in the art together with a pharmaceutically acceptable carrier for the treatment of neurodegenerative diseases.
  • the carrier includes all kinds of solvents, dispersion media, oil-in-water or water-in-oil emulsions, aqueous compositions, liposomes, microbeads and microsomes.
  • it is formulated using a transfection reagent, and can be delivered to cells using subcutaneous, blood, bone marrow, or abdominal cavity.
  • the pharmaceutical composition according to the present invention may be administered to a patient in a pharmaceutically effective amount, that is, in an amount sufficient to prevent or relieve symptoms and treat neurodegenerative diseases.
  • a typical daily dosage may be administered in the range of about 0.01 to 1000 mg/kg, and preferably, it may be administered in the range of about 1 to 100 mg/kg.
  • the pharmaceutical composition of the present invention can be administered in one or several divided doses within a preferred dosage range.
  • the dosage of the pharmaceutical composition according to the present invention may be appropriately selected by a person skilled in the art according to the route of administration, the subject of administration, age, sex, weight, individual differences, and disease conditions.
  • the route of administration may be administered orally or parenterally.
  • Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual, rectal, or pancreatic It may be intravenous administration, but is not limited thereto.
  • powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, suspensions, wafers according to a method known in the art together with a suitable carrier for oral administration. It can be formulated in the form of such as.
  • suitable carriers include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, cellulose, Fillers such as celluloses including methyl cellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, gelatin, and polyvinylpyrrolidone may be included. In addition, in some cases, cross-linked polyvinylpyrrolidone, agar, alginic acid or sodium alginate may be added as a disintegrant. Furthermore, the pharmaceutical composition may further include an anti-aggregating agent, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and a preservative.
  • the pharmaceutical composition of the present invention when administered parenterally, can be formulated according to a method known in the art in the form of injections, transdermal administrations and nasal inhalants together with a suitable parenteral carrier.
  • the pharmaceutical composition can be administered by any device capable of moving the active substance to the target cell.
  • Preferred modes of administration and formulations are intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections or instillations.
  • Injectables include aqueous solvents such as physiological saline or ring gel solution, vegetable oils, higher fatty acid esters (e.g., oleic acid ethyl, etc.), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, or glycerin), and other non-aqueous solvents.
  • Stabilizers for preventing deterioration e.g., ascorbic acid, sodium hydrogen sulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.
  • emulsifiers e.g., ascorbic acid, sodium hydrogen sulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.
  • buffers for pH control emulsifiers
  • buffers for pH control e.g., buffers for pH control
  • Pharmaceutical carriers such as preservatives (eg, mercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.) may be included.
  • suitable carriers for injections include, but are not limited to, water, ethanol, polyol (eg, glycerol, propylene glycol and liquid polyethylene glycol, etc.), a mixture thereof and/or a solvent or dispersion medium containing vegetable oil.
  • suitable carriers include isotonic solutions such as Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) containing triethanolamine or sterile water for injection, 10% ethanol, 40% propylene glycol and 5% dextrose. Etc. can be used.
  • the injection may further include an isotonic agent such as sugar or sodium chloride in most cases.
  • transdermal administration ointments, creams, lotions, gels, external solutions, pasta, liniment, air rolls, and the like are included.
  • transdermal administration means that the active ingredient in an effective amount contained in the pharmaceutical composition is delivered into the skin by topically administering the pharmaceutical composition to the skin.
  • the pharmaceutical composition of the present invention may be prepared in an injectable formulation and administered by lightly pricking the skin with a 30 gauge thin injection needle or applying it directly to the skin. These formulations are described in prescriptions generally known in pharmaceutical chemistry.
  • the compounds used according to the invention can be used in pressurized packs or with suitable propellants, for example dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. It can be conveniently delivered from a nebulizer in the form of an aerosol spray.
  • the dosage unit can be determined by providing a valve that delivers a metered amount.
  • gelatin capsules and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mixture of the compound and a suitable powder base such as lactose or starch.
  • compositions according to the present invention include one or more buffers (e.g., saline or PBS), carbohythrate (e.g., glucose, mannose, sucrose or dextran), antioxidants, bacteriostatic agents, chelating agents (e.g. For example, EDTA or glutathione), adjuvants (eg, aluminum hydroxide), suspending agents, thickening agents and/or preservatives may further be included.
  • buffers e.g., saline or PBS
  • carbohythrate e.g., glucose, mannose, sucrose or dextran
  • antioxidants e.g., bacteriostatic agents, chelating agents (e.g. For example, EDTA or glutathione), adjuvants (eg, aluminum hydroxide), suspending agents, thickening agents and/or preservatives may further be included.
  • bacteriostatic agents e.g., EDTA or glutathione
  • adjuvants
  • compositions of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
  • composition of the present invention may be administered alone or may be administered in combination with a known compound having an effect of treating neurodegenerative diseases.
  • (c) It provides a screening method for a neurodegenerative disease treatment comprising the step of selecting a test substance that reduces the expression level of CD9 protein or mRNA compared to the control cell as a candidate substance for treatment of neurodegenerative disease.
  • the step (a) is a step of contacting cells expressing CD9 protein or mRNA in order to determine whether the test substance to be analyzed has an activity to inhibit the expression of CD9 protein or mRNA.
  • 'contacting' or'treatment' is a general meaning, and two or more agents (e.g., two polypeptides) are combined, or an agent and a cell (e.g., Protein and cell).
  • Contact can occur in vitro. For example, combining two or more agents in a test tube or other container, or combining a test agent with cells or cell lysates and a test agent. Contact can also occur in cells or in situ.
  • two polypeptides are brought into contact in a cell or cell lysate by coexpressing a recombinant polynucleotide encoding two polypeptides in a cell.
  • a protein chip or a protein array in which the protein to be tested is arranged on the surface of a stationary bed may be used.
  • the'test substance' can be used interchangeably with a test agent or agent, and any substance, molecule, element, compound ( Includes a compound, entity, or combination thereof. Examples include proteins, polypeptides, small organic molecules, polysaccharides, and polynucleotides. It may also be a natural product, a synthetic compound or a chemical compound, or a combination of two or more substances.
  • Test formulations can be synthetic or natural. The test formulations can be obtained from a wide variety of sources, including libraries of synthetic or natural compounds. Combinatorial libraries can be produced from several types of compounds that can be synthesized in a step-by-step manner.
  • Compounds of multiple combinatorial libraries can be prepared by the encoded synthetic libraries (ESL) method (WO 95/12608, WO93/06121, WO 94/08051, WO95/395503 and WO 95/30642).
  • Peptide libraries can be prepared by the phage display method (WO91/18980).
  • Libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts can be obtained from commercial sources or collected in the field.
  • Known pharmacological agents can be directed or applied to a random chemical modification, such as acylation, alkylation, esterification, amidification, to prepare structural analogues.
  • the test agent may be a naturally occurring protein or fragment thereof. Such test formulations can be obtained from natural sources, such as cell or tissue lysates. Libraries of polypeptide preparations can be produced, for example, by conventional methods or obtained from commercially available cDNA libraries.
  • the test agent may be a peptide, such as a peptide having about 5 to 30 amino acids, preferably about 5 to 20, more preferably about 7 to 15 amino acids.
  • the peptide may be a naturally occurring protein, a random peptide, or a cut product of a'biased' random peptide.
  • the test agent may be a nucleic acid.
  • the nucleic acid test agent can be a naturally occurring nucleic acid, a random nucleic acid, or a'biased' random nucleic acid.
  • cuts of prokaryotic or eukaryotic genomes can be used analogously to those described above.
  • test agent may be a small molecule (eg, a molecule having a molecular weight of about 1,000 Da or less).
  • a high throughput assay may be preferably applied to a method for screening a small molecule modulating agent. Many assays are useful for this screening.
  • the CD9-expressing cell may be a cell that internally expresses CD9, or may be a cell that overexpresses CD9 by being transformed with a recombinant expression vector containing a polynucleotide encoding CD9.
  • the cells expressing the CD9 gene may be fibroblasts.
  • Step (b) is a step of measuring the gene expression level of CD9 in cells expressing CD9 contacted with the test substance and cells expressing CD9 without contact with the test substance.
  • the measurement of CD9 mRNA expression can be performed without limitation, using conventional methods for determining the expression level in the art, and examples of analysis methods include reverse transcription polymerase chain reaction (RT-PCR), competitive RT-PCR (competitive RT-PCR), real-time RT-PCR, RNase protection assay (RPA), northern blotting, DNA microarray chip, RNA sequencing (RNA) sequencing) and the like, but are not limited thereto.
  • RT-PCR reverse transcription polymerase chain reaction
  • competitive RT-PCR competitive RT-PCR
  • RNase protection assay RNase protection assay
  • northern blotting DNA microarray chip
  • RNA sequencing (RNA) sequencing) and the like but are not limited thereto.
  • methods for measuring the expression level of CD9 protein can be used without limitation, methods known in the art, such as western blotting, dot blotting, and enzyme-linked immunosorbent assay. ), Radioactive Immunoassay (RIA), Radioimmune Diffusion Method, Ouchteroni Immunity Diffusion Method, Rocket Immunoelectrophoresis, Immunohistochemical Staining, Immunoprecipitation, Complement Fixation Assay, Flow Cytometry (FACS) or Protein Chip Method And the like, but are not limited thereto.
  • the step (c) is a step of selecting a test substance that reduces the expression level of CD9 protein or mRNA compared to the control cells as a candidate substance for treating neurodegenerative diseases.
  • the present invention provides a use of a CD9 protein expression or activity inhibitor for preparing a preparation for preventing or treating neurodegenerative diseases.
  • the present invention provides a method for treating neurodegenerative diseases comprising administering an effective amount of a composition comprising an inhibitor of expression or activity of a CD9 protein as an active ingredient to an individual in need thereof.
  • The'effective amount' of the present invention refers to an amount showing an effect of improving, treating, preventing, detecting, diagnosing, or inhibiting or reducing neurodegenerative diseases when administered to an individual, and the'individual' is an animal, preferably For example, it may be an animal including a mammal, especially a human, and may be a cell, tissue, organ, etc. derived from an animal. The individual may be a patient in need of the effect.
  • The'treatment' of the present invention generally refers to improving the symptoms of neurodegenerative diseases or neurodegenerative diseases, which may include curing, substantially preventing, or improving the condition, It includes, but is not limited to, alleviating, curing, or preventing one symptom or most of the symptoms resulting from neurodegenerative disease.
  • Substances that inhibit the expression or activity of CD9 have the effect of improving the memory of patients with neurodegenerative diseases and can be usefully used in the development of treatments for neurodegenerative diseases, and candidates for treatment of neurodegenerative diseases through analysis of the expression level of CD9 Can be screened.
  • Figure 3 shows tau phosphorylation according to treatment with anti-CD9 antibody in AD fibroblasts.
  • FIG. 4A to 4F show the effect of improving memory by administering anti-CD9Ab.
  • Each general motor activity Fig. 4A.
  • the number of alternating repetitions of mice administered with the drug Fig. 4b
  • contextual recall Fig. 4c
  • freezing time Fig. 4d
  • the number of arrivals to the target area in the Morris water maze Fig. 4e
  • the time spent in Fig. 4f was measured.
  • mice Female 3xTg mice (JAX 004807) were used as experimental animals. Experimental animals were provided with sterile feed and water, and were reared with less than 10 animals each. The day and night cycle was set to 12 hours. Animal experiments were conducted in an animal breeding facility at Korea University under the guidance and supervision of the Animal Experimental Ethics Committee, and animal experiments were performed according to the protocol approved by Korea University IACUC.
  • AD fibroblasts purchased from Coriell (Camden, NJ), (AG07374(AD fibroblast 1), AG05770(AD fibroblast 2)) age-control fibroblasts (AG09857), and normal human tonsils extracted in this laboratory. Fibroblasts were used.
  • Mouse control IgG1, anti-CD9 ALB6 (Immunotech) was used as the primary antibody, and goat anti-mouse IgG (Jackson Immunoresearch) labeled with FITC was used as the secondary antibody.
  • Cells were prepared by adding trypsin-EDTA to fibroblasts in culture. Half of the cells were treated with FACS permeabilizing solution 2 purchased from Becton Dickinson Bioscience for 15 minutes, and the other half was left at 4°C. The cells were washed with PBS containing 1% Fetal bovine serum (FBS) and 0.05% sodium azide, transferred to a FACS tube, and reacted with the primary antibody at 4°C for 15 minutes. After washing with FACS wash buffer, secondary antibody was added and reacted at 4° C. for 15 minutes. After washing with FACS buffer, CD9 expression was analyzed with BD FACSCalibur.
  • FBS Fetal bovine serum
  • the Y-maze device consisted of three arms 32 cm (length) x 10 cm (width) with 26 cm walls (San Diego Instruments, San Diego, CA). Each mouse was placed in the center of the Y-maze and allowed to move freely through the maze for 5 minutes. It was considered effective if all four paws of the mouse entered the arm of the maze. Alternation was defined as entering 3 different arms (i.e. 1, 2, 3 or 2, 3, 1, etc.) in 3 succession. The percentage shift score was calculated using the following formula.
  • spontaneous alternation% (number of spontaneous)/(total number of arm entries -2) x 100
  • the total number of arms was used as a measure of the general activity of the animal.
  • the maze was cleaned with 70% ethanol to minimize the odor signal.
  • the device used was a white round plastic tank (122 cm in diameter) with a wall of 76 cm, filled with water held at 22u +/- 22uC, made opaque by adding non-toxic white paint, and a detachable square inside (side 10 cm long) Plexiglas platform.
  • the tank was in a test room containing a number of visible visual cues. Mice were placed on the platform for 10 seconds before the first test of the first session. Mice were trained to swim on a platform submerged 1.5 cm below the surface of the water. The platform was in a fixed position equidistant from the center and wall of the tank. Mice were trained three times a day. During each training period, mice were placed in tanks in random order at one of the four designated starting points.
  • mice The mouse was allowed to find and escape from the submerged platform. If the platform was not found within 60 seconds, it was manually guided to the platform and left there for 10 seconds. Mice were trained to reach a training criterion of 20 seconds (escape waiting time). Mice were evaluated in the probe test for 24 hours after the last training session and consisted of 60 seconds of free swimming in a platformless pool. The performance of each animal acquisition parameters provide data on (waiting to find the platform and distance tracking time), and probe-trial parameters (the number of entries for the target platform area) Any-Maze TM video tracking system (Stoelting Co .) was used.
  • Protein concentration was quantified using Bradford Assay (Bio-Rad Protein Assay 500-0006, Germany, Munchen), and total cell proteins, age-control fibroblasts, and AD-fibroblasts were isolated with 8-10% SDS polyacrylamide gel. .
  • Polyvinylidene difluoride (PVDF) membrane was blocked in Tris buffered saline (5% no fat formula, 0.1% Tween20).
  • As the primary antibody anti PHF-tau clone AT8 (MN1020, Thermo Scientific, Rockford, USA), p Tau pSer422 (T7944, Sigma), anti-tau clone tau-5 (MAB361, Millipore Billerica, Ma), CD9 were used. I did. All smears were standardized with actin (MAB1501, Chemicon-Millipore, Billerica, Ma).
  • CD9 still did not express age-control fibroblast.
  • AD fibroblast 1 which showed relatively lower expression of CD9 than AD fibroblast 2 in cell membranes, was hardly expressed even after permeabilization. It is believed that the CD9 molecules on the cell surface and inside the cell were lost in the permeabilization step. Meanwhile, it was found that CD9, a cell membrane protein, was expressed at a high level in AD fibroblast 2 after permeabilization. It was interpreted that the CD9 protein, which normally exists only in the cell membrane, is also present in the nucleoplasm or the nucleus, depending on the progression of alzheimer's disease.
  • NFTs neurofibrillary tangles
  • tau hyperphosphorylation is associated with changes in microtubule assembly leading to neurofibrillary tangles (NFTs) and neurodegeneration in Alzheimer's disease. have. In addition, it has been linked to many other neurological disorders, including Alzheimer's and Parkinson's.
  • the level (control lane) of phosphorylated tau (p-Ser422) in AD fibroblasts was significantly increased compared to age control fibroblasts (not shown).
  • the antibody was administered, it was confirmed that it was significantly reduced (anti-CD9-Ab panel), but the total amount of tau did not show any significant change (FIG. 3 ).
  • mice Four Tg mice (3xTg+Ab) treated with anti-CD9 Ab in Y-maze and the group treated with placebo (3xTg) had no significant difference in total cancer entry and exit, so there was no difference in general exercise activity. It was found (Fig. 4A). However, the number of alternating repetitions of the mice administered with the drug was higher than that of the control group and the percentage value was higher (Fig. 4B, # p ⁇ 0.05).
  • mice were tested at baseline spatial memory function using the Morris water maze. In this study, we performed a visible platform training, followed by a hidden platform test with four probe attempts per day. All mice in each group were able to reach the training criterion within 4 days and similarly displayed skilled swimming ability. However, in the probe test, 3xTg mice treated with anti-CD9Ab showed a significant increase in the number of arrivals to the target area and time spent in the target area when compared to the control group (Fig. 4E, 4F, # p ⁇ 0.05).
  • Substances that inhibit the expression or activity of CD9 have the effect of improving the memory of patients with neurodegenerative diseases and can be usefully used in the development of treatments for neurodegenerative diseases, and candidates for treatment of neurodegenerative diseases through analysis of the expression level of CD9 It has high industrial applicability because it can screen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

La présente invention concerne une composition pour la prévention ou le traitement de maladies neurodégénératives utilisant la protéine CD9, et un procédé de criblage d'un agent thérapeutique contre les maladies neurodégénératives et, plus spécifiquement, une composition pharmaceutique pour la prévention ou le traitement de maladies neurodégénératives comprenant, en tant que principe actif, un inhibiteur de l'expression ou de l'activité de la protéine CD9, et un procédé de criblage d'un agent thérapeutique contre les maladies neurodégénératives. Une substance destinée à inhiber l'expression ou l'activité de la protéine CD9 a pour effet d'améliorer la mémoire des patients atteints de maladies neurodégénératives, et peut donc être utilisée efficacement dans le développement d'un agent thérapeutique contre les maladies neurodégénératives, et grâce à l'analyse du niveau d'expression de la protéine CD9, des substances candidates aptes à être utilisées en tant qu'agent thérapeutique contre les maladies neurodégénératives peuvent être criblées.
PCT/KR2020/005155 2019-04-18 2020-04-17 Composition pour la prévention ou le traitement de maladies neurodégénératives utilisant la protéine cd9 et procédé de criblage d'un agent thérapeutique contre les maladies neurodégénératives WO2020213982A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190045489A KR20200122601A (ko) 2019-04-18 2019-04-18 Cd9을 이용한 퇴행성 신경질환의 예방 또는 치료용 조성물과 퇴행성 신경질환 치료제 스크리닝 방법
KR10-2019-0045489 2019-04-18

Publications (1)

Publication Number Publication Date
WO2020213982A1 true WO2020213982A1 (fr) 2020-10-22

Family

ID=72837530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/005155 WO2020213982A1 (fr) 2019-04-18 2020-04-17 Composition pour la prévention ou le traitement de maladies neurodégénératives utilisant la protéine cd9 et procédé de criblage d'un agent thérapeutique contre les maladies neurodégénératives

Country Status (2)

Country Link
KR (1) KR20200122601A (fr)
WO (1) WO2020213982A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024147597A1 (fr) * 2023-01-03 2024-07-11 서울대학교산학협력단 Utilisation de l'expression de fgfr3 ou d'un inhibiteur d'activité pour le traitement de maladies neurodégénératives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161584A1 (en) * 2003-12-26 2007-07-12 Kenichiro Kosai Drug for preventing or treating heart diseases comprising cd9 gene
KR101227971B1 (ko) * 2008-06-25 2013-01-30 성균관대학교산학협력단 Ｃｄ９―특이적인 인간항체
WO2016021894A1 (fr) * 2014-08-04 2016-02-11 영남대학교 산학협력단 Composition pharmaceutique pour prévenir ou traiter une sénescence cellulaire ou des maladies associées à la sénescence, contenant un anticorps cd9 comme principe actif
KR20160068964A (ko) * 2013-10-24 2016-06-15 나노소믹스 인코포레이티드 알쯔하이머병 및 다른 신경퇴행성 장애에 대한 바이오마커 및 진단 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161584A1 (en) * 2003-12-26 2007-07-12 Kenichiro Kosai Drug for preventing or treating heart diseases comprising cd9 gene
KR101227971B1 (ko) * 2008-06-25 2013-01-30 성균관대학교산학협력단 Ｃｄ９―특이적인 인간항체
KR20160068964A (ko) * 2013-10-24 2016-06-15 나노소믹스 인코포레이티드 알쯔하이머병 및 다른 신경퇴행성 장애에 대한 바이오마커 및 진단 방법
WO2016021894A1 (fr) * 2014-08-04 2016-02-11 영남대학교 산학협력단 Composition pharmaceutique pour prévenir ou traiter une sénescence cellulaire ou des maladies associées à la sénescence, contenant un anticorps cd9 comme principe actif

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM, TAE WOO ET AL.: "Identification of replicative senescence-associated genes in human umbilical vein endothelial cells by an annealing control primer system", EXPERIMENTAL GERONTOLOGY, vol. 43, 2008, pages 286 - 295, XP022523981, DOI: 10.1016/j.exger.2007.12.010 *

Also Published As

Publication number Publication date
KR20200122601A (ko) 2020-10-28

Similar Documents

Publication Publication Date Title
WO2014182051A1 (fr) Composition comprenant un inhibiteur asm comme principe actif pour prévenir ou traiter des troubles neurologiques dégénératifs
WO2018139819A1 (fr) Utilisations pour la prévention ou pour le traitement de maladies cérébrales à l'aide de micro-arn
JP2014511391A (ja) Ｔｆｅｂリン酸化阻害剤およびその使用
WO2019194586A1 (fr) Nouvelle cible pour lutter contre le cancer et renforcer l'immunité
KR20190110938A (ko) Cox2 아세틸화제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
WO2020213982A1 (fr) Composition pour la prévention ou le traitement de maladies neurodégénératives utilisant la protéine cd9 et procédé de criblage d'un agent thérapeutique contre les maladies neurodégénératives
WO2021177518A1 (fr) Composition pharmaceutique pour abaisser le cholestérol sanguin, prévenir ou traiter des maladies cardiovasculaires et réduire l'inflammation
CA2989052A1 (fr) Ligands ppar-alpha derives du cerveau
WO2020159191A1 (fr) Composition comportant mls-stat3 pour la prévention ou le traitement d'une maladie immunitaire
WO2019235876A1 (fr) Composition pharmaceutique comprenant un inhibiteur de l'expression ou de l'activité de c-src permettant de prévenir ou de traiter une synucléinopathie
WO2010021516A9 (fr) Nouvelle utilisation de lipocaline 2 pour traiter des lesions cérébrales
WO2020017788A1 (fr) Composition pour la prévention ou le traitement du diabète à l'aide de cd9 et procédé de criblage d'agents antidiabétiques
WO2018212503A1 (fr) Protéine cotl1 impliquée dans le maintien de l'homéostasie d'une cellule souche hématopoïétique, et utilisation associée
WO2022216096A1 (fr) Nouvelle cible pour effet anticancéreux et renforcement de l'immunité
WO2021246755A1 (fr) Composition pour prévenir, soulager ou traiter une maladie métabolique, comprenant un inhibiteur de la phospholipase d2
WO2022098118A1 (fr) Composition de régulation de différentiation d'ostéoclastes et utilisation associée
WO2019066519A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la dégénérescence maculaire liée à l'âge contenant un complexe d'arn ciblant le facteur de croissance du tissu conjonctif
WO2022005214A1 (fr) Kit de criblage pour agent thérapeutique pour une maladie à coronavirus employant une activité estérase de protéine de spicule de virus de covid-19, et utilisation de la substance criblée en employant d'un kit pour la prévention, l'atténuation ou le traitement d'une maladie à coronavirus
KR101341200B1 (ko) Ｔｒａｐ８０ 조절제를 유효성분으로 함유하는 대사증후군 치료 또는 예방용 약학조성물
WO2017023001A1 (fr) Protéine 14-3-3 à rôle régulateur de la stéatose hépatique non alcoolique
WO2017023002A1 (fr) Protéine 14-3-3 utilisée comme facteur de régulation de la stéatose hépatique non alcoolique
WO2020197367A1 (fr) Composition pour la prévention ou le traitement du diabète à l'aide de st8sia1, et procédé de criblage d'agents antidiabétiques
WO2015056970A1 (fr) Composition pour la prévention ou le traitement de l'ostéoporose, contenant un inhibiteur de progranuline comme principe actif
WO2015111971A1 (fr) Composition pharmaceutique contenant un ligand gpr119 comme principe actif pour prévenir ou traiter une stéatose hépatique non alcoolique
WO2009136752A9 (fr) Nouveau peptide pour augmenter l'expression de la protéine du facteur neurotrophique dérivé du cerveau (bdnf) dans les neurones hippocampiques, le tissu hippocampique et le tissu du cortexe cérébral

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20791147

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20791147

Country of ref document: EP

Kind code of ref document: A1